Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01672255 · ClinicalTrials.gov registry record · Early Phase 1

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)

A Early Phase 1 study, sponsored by University of Maryland, Baltimore.

Completed
Registry status
Early Phase 1
Development phase
64
Enrollment target

NCT01672255: Completed Early Phase 1 study, sponsored by University of Maryland, Baltimore.

NCT01672255 is a Early Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 64 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (21% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01672255, a Early Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
Early Phase 1
Development phase
64 participants
Enrollment target

Study Summary

Exercise is a cornerstone of diabetes management. It helps reduce blood pressure, promote weight loss, lower insulin resistance and improve glucose and lipid (triglyceride and HDL-cholesterol) profiles. Unfortunately, the benefits of exercise are often not embraced by diabetic individuals because of the fear of low blood sugar (hypoglycemia). My laboratory has demonstrated that Autonomic nervous system (ANS) counterregulatory failure plays an important role in exercise associated hypoglycemia in Type 1 DM. ANS responses are significantly reduced in Type 1 DM and are further blunted by antecedent episodes of hypoglycemia. Furthermore, there is a large sexual dimorphism of reduced ANS responses during submaximal exercise in both Type 1 DM and healthy individuals that is unexplained. Accumulating data are demonstrating that serotonergic pathways can regulate ANS discharge. Generally, serotonergic pathways are inhibitory but both single and longer term administration of selective serotonin reuptake inhibitors (SSRI's) such as Prozac has been demonstrated to increase basal epinephrine levels and enhance baroreflex control of Sympathetic nervous system (SNS) activity. What is unknown is whether fluoxetine can also enhance SNS responses and also override the large ANS sexual dimorphism present during sub maximal exercise. Therefore, the purpose of this study is to determine if the SSRI fluoxetine (Prozac) can improve SNS responses during exercise.

Primary Outcome

This change in catecholamines will be compared to another 90 minute experimental period after 8 weeks administration of SSRI or placebo.

Interventions

  • DRUG Placebo control
  • DRUG Fluoxetine

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2012-10
Est. Completion 2025-05
Phase Early Phase 1
University of Maryland, Baltimore

560 total trials

What the finished NCT01672255 record still lists

NCT01672255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (21% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo control is the first listed.

NCT01672255 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01672255 about?

NCT01672255 is a clinical study titled "Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)". Exercise is a cornerstone of diabetes management. It helps reduce blood pressure, promote weight loss, lower insulin resistance and improve glucose and lipid (triglyceride and HDL-cholesterol) profiles. Unfortunately, the benefits of exercise are often not embraced by diabetic individuals because of...

What is the current status of trial NCT01672255?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 64 participants. The study started on 2012-10. Estimated completion is 2025-05.

What interventions are being tested in trial NCT01672255?

The interventions under investigation include: Placebo control (DRUG), Fluoxetine (DRUG).

Who is sponsoring clinical trial NCT01672255?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01672255's enrollment target sits among peer trials

64 377th of 2000 higher than 1,614 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01672255, the US trial registry maintained by the National Library of Medicine. NCT01672255 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.